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Abstract
The coronavirus disease-2019 (COVID-19) pandemic has strained health care
resources around the world, causing many institutions to curtail or stop elective
procedures. This has resulted in an inability to care for patients with valvular and
structural heart disease in a timely fashion, potentially placing these patients at
increased risk for adverse cardiovascular complications, including CHF and death.
The effective triage of these patients has become challenging in the current envi-
ronment, as clinicians have had to weigh the risk of bringing susceptible patients
into the hospital environment during the COVID-19 pandemic against the risk of
delaying a needed procedure. In this document, the authors suggest guidelines for
how to triage patients in need of structural heart disease interventions and provide
a framework for how to decide when it may be appropriate to proceed with inter-
vention despite the ongoing pandemic. In particular, the authors address the triage
of patients in need of transcatheter aortic valve replacement and percutaneous
mitral valve repair. The authors also address procedural issues and considerations
for the function of structural heart disease teams during the COVID-19 pandemic.
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1 | INTRODUCTION
The coronavirus disease-2019 (COVID-19) pandemic has put an enor-
mous strain on health care systems worldwide. Hospitals in China,
Italy, Spain, and now the United States have experienced surges of
critically ill patients with COVID-19, which has resulted in a dramatic
depletion of hospital resources, infection of health care personnel,
and critical shortages of vital resources, including personal protective
equipment (PPE), ventilators, and intensive care unit (ICU) beds.
Capacity has also become limited to provide care for patients with
serious comorbid conditions in need of urgent care not related to
COVID-19. To preserve PPE and prepare for the potential surge of
COVID-19 patients to U.S. hospitals, the Centers for Medicare and
Medicaid Services has asked for a deferral of nonessential procedures
and operations.1 Patients who are in need of structural heart disease
(SHD) intervention constitute a particularly challenging group, as
many of them have conditions that may be life threatening if interven-
tion is inappropriately delayed. Therefore, decisions regarding the
timing of SHD interventions must consider the risk of delaying the
procedure, the risk for the patient of COVID-19 exposure outside of
the home shelter, and the use of limited hospital resources. Com-
pounding this challenge is the geographic variation in the peak of the
pandemic within the United States and the significant delay in the res-
toration of normal health care operations after the immediate threat
has passed. The length of this delay is unknown but could be many
months subsequent to the peak, which poses distinct challenges for
rescheduling procedures. The purpose of this article is to provide a
framework for SHD teams to triage patients in need of SHD interven-
tion during the COVID-19 pandemic and to discuss the evaluation
and procedural considerations for these patients.
The general priorities are (a) to minimize exposure to coronavirus
for patients with SHD and the structural interventional team; (b) to
maintain high-quality and durable structural interventional outcomes
in those who do require procedures during the pandemic; (c) to
reduce the risk that these patients with SHD use resources that might
be needed for patients with COVID-19; and (d) to prevent delay of
intervention in patients at particularly high risk for clinical deteriora-
tion, heart failure, and death. It is understood that for any individual
patient, local clinical judgment based on the impact of the COVID-19
pandemic in the region and institution should ultimately guide the
evaluation and treatment pathway.
2 | TRANSCATHETER AORTIC VALVE
REPLACEMENT
Given advanced age and comorbidities, many patients with severe
symptomatic aortic stenosis (AS) are at increased risk for COVID-19
complications and death. However, multiple studies have also shown
higher mortality among patients with severe symptomatic AS with a
delay in treatment2,3 over several months to years rather than weeks.
This writing group proposes the following for the timing of trans-
catheter aortic valve replacement (TAVR) for patients with severe AS
during the COVID-19 pandemic.
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2.1 | Symptomatic severe AS
For inpatients with severe symptomatic AS associated with a reduc-
tion in ejection fraction thought to be secondary to AS, presence of
New York Heart Association functional class III or IV congestive heart
failure (CHF), or syncope secondary to AS, TAVR should be consid-
ered to decrease the risk for clinical deterioration, prolonged hospital
stay, or repeat hospitalization. It would be reasonable to schedule
TAVR for outpatients with severe to critical AS and class III or IV CHF
symptoms or syncope due to AS.
2.2 | Minimally symptomatic severe to critical AS
For patients with New York Heart Association functional class I or II
CHF symptoms and quantitative measures of valve severity that indi-
cate a critically tight valve, it is reasonable to consider either urgent
TAVR or close outpatient virtual monitoring by the valve coordinator.
Data to date are not robust enough to give firm recommendations,
but features that warrant consideration of TAVR include particularly
high peak or mean gradient, very small calculated aortic valve area,
and very low dimensionless index.
2.3 | Asymptomatic severe to critical AS
For truly asymptomatic patients, it is reasonable to postpone consid-
eration of TAVR for 3 months or until after hospital operations
resume elective procedures. Close outpatient monitoring, possibly via
telehealth, should continue for all patients with severe AS.
TAVR centers should establish a system that provides weekly
telephone follow-up for patients whose procedures have been
deferred. It is expected that some of these patients will develop wors-
ening of their symptoms and will require the procedure to be per-
formed more urgently during the pandemic. We recommend that the
TAVR team convene virtually on at least a weekly basis to review the
status of patients on the “waiting” list. A single interventional cardiolo-
gist and the cardiac surgeon should assume a leadership position and
be given the authority to arbitrate challenging cases. No triage system
can accurately identify all patients who may be safely deferred; the
triage system will need to be individualized to each medical center,
institutional valve program, and patient population served, as well as
the pandemic's local impact.
2.4 | Procedural considerations for TAVR during
the COVID-19 pandemic
There should be no compromise in the quality of interventional care
provided to TAVR patients during the COVID-19 pandemic. The
majority of TAVR procedures can be performed using a minimalist
approach, with moderate conscious sedation. Recent data from the
Transcatheter Valve Therapy (TVT) Registry have shown a steady
increase in the use of moderate sedation for TAVR, with improved
safety and recovery.4,5 The majority of TAVR procedures do not
require ICU recovery after the procedure, and this is important as crit-
ical care beds will be limited during the COVID-19 crisis in parts of
the country. Percutaneous coronary intervention should be performed
prior to TAVR only when coronary artery disease is contributing to
the patient's clinical presentation or would pose a high risk for the
TAVR procedure. Otherwise, percutaneous coronary intervention may
be safely deferred.6,7
3 | TRANSCATHETER MITRAL VALVE
PROCEDURES
3.1 | Percutaneous mitral valve repair
The majority of percutaneous mitral valve repair (edge-to-edge repair)
can be safely deferred. The following groups of patients should be con-
sidered for treatment with edge-to-edge repair during the COVID-19
pandemic: (a) inpatients with severe functional mitral regurgitation
(MR) (3+/4+) who cannot be safely discharged despite optimized
guideline-directed medical therapy by a heart failure specialist;
(b) outpatients with severe functional MR (3+/4+) with hospitalization
for CHF within 30 days despite optimized guideline-directed medical
therapy by a heart failure specialist; (c) inpatients with CHF and severe
degenerative MR (3+/4+) due to acute valvular dysfunction
(i.e., secondary to ruptured chord or papillary muscle rupture after myo-
cardial infarction) who are at high risk for surgical mitral valve repair or
replacement; (d) outpatients with severe degenerative MR (3+/4+) with
hospitalization within 30 days despite optimized medical therapy who
are high risk for surgical mitral valve repair or replacement; and
(e) patients with either severe degenerative MR or functional MR who
are in low-output, decompensated heart failure requiring ICU-level care
for whom edge-to-edge device implantation might improve hemody-
namic status for extubation and/or transfer out of the ICU setting.
It is the responsibility of the procedural team to keep in contact
with patients who are deferred on a weekly basis to ensure that there
has been no decompensation requiring earlier intervention.
3.2 | Valve-in valve transcatheter mitral valve
replacement
Valve-in-valve transcatheter mitral valve replacement (TMVR) is the
only other transcatheter mitral valve intervention that is currently
approved by the U.S. Food and Drug Administration. Because these
procedures are resource intensive, they should be deferred until after
the COVID-19 pandemic has adequately resolved, provided such mitral
valve patients can be sufficiently managed on medical therapy in the
interim. Valve-in-valve TMVR during the COVID-19 pandemic should
be considered for patients with severe bioprosthetic mitral stenosis or
MR who are inpatients with CHF or outpatients who have had hospital-
izations for CHF within 30 days despite optimized guideline-directed
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medical therapy. Valve-in-ring TMVR and valve-in-mitral annular calcifi-
cation TMVR are off-label procedures and pose a much higher risk for
complications that may prolong hospitalization.8,9 These latter proce-
dures should be generally avoided during the COVID-19 pandemic.
4 | PARAVALVULAR LEAK CLOSURE
Paravalvular leak closure (particularly mitral) is generally a lengthy pro-
cedure and requires general anesthesia and transesophageal echocardi-
ography (TEE). Patients with significant paravalvular leaks but with
symptoms that can be managed medically should be deferred until after
the moratorium on nonessential procedures has been removed.
Patients who should be considered for paravalvular leak closure during
the COVID-19 pandemic are inpatients with CHF and/or hemolysis.
5 | OTHER SHD INTERVENTIONS
Other commonly performed SHD interventions include patent fora-
men ovale closure, atrial septal defect closure, left atrial appendage
occlusion, and alcohol septal ablation for hypertrophic cardiomyopa-
thy. These procedures treat conditions that rarely result in hospitaliza-
tion or death without the procedure over the short term. For these
reasons, these procedures should be deferred until it is deemed safe
to resume performing nonemergent procedures in procedural suites.
6 | INTRAPROCEDURAL IMAGING
CONSIDERATIONS
To offset the risk for particulate aerosolization, pre-procedural TEE
should be limited in use. If a patient is planned for an emergent percu-
taneous mitral valve repair procedure, on-table TEE will suffice in case
of planning at experienced centers. For any high-risk SHD procedure
requiring interventional imaging support with TEE, emphasis must be
placed on the availability of full PPE for the interventional imager. The
major aerosolization risk to the interventional imager and cardiac
anesthesia team occurs during the initial intubation and any tran-
sesophageal probe manipulation thereafter in a nonintubated patient.
In an already ventilated patient, care should be made that a high-
efficiency particulate air filter is placed with the endotracheal tube to
maximize the safety of the SHD team at the head of the patient's bed.
In the absence of sufficient PPE, alternative imaging modalities should
be considered (intracardiac echocardiography if possible), as there is a
high risk for COVID-19 exposure with the performance of TEE.
7 | OUTPATIENT CLINICS
The SHD clinic is a vital entry point for patients with valvular heart dis-
ease and SHD into the health care system. In preparation for a proce-
dure, patients require visits with multiple physicians and additional visits
for imaging. Having patients make multiple trips to the hospital should
be avoided during the COVID-19 pandemic to minimize the risk for virus
transmission among inpatients, outpatients, and health care personnel.
The SHD clinic should help coordinate visits for patients with SHD, and
efforts should be made to use telemedicine for consultations. If a patient
requires treatment during the COVID-19 pandemic, pre-procedural visits
and imaging should be consolidated to a single hospital encounter prior
to the procedure if possible. It will be important to maintain typical SHD
clinic volumes with virtual visits during the pandemic so that preparations
can be made to treat patients in need of SHD intervention as soon as
possible once normal hospital operations are restored. Recently, the Soci-
ety of Thoracic Surgeons/American College of Cardiology TVT Registry
allowed the substitution of in-person visits with telephone or virtual
visits for the 30-day and 1-year follow-up visits. Although some elements
of these registries cannot be collected with remote follow-up, this will
need to be addressed at a future date.
8 | SHD TEAM PERSONNEL
SHD clinics and procedures are sustained through a multidisciplinary
heart team process. This team consists of interventional cardiologists,
cardiac surgeons, cardiac imaging specialists, anesthesiologists, and
nurse specialists. Depending on the workflows and potential exposure
both within the hospital (as rates of exposure-based infections to
health care workers remain high during this pandemic) and outside
the workplace, team members may need to be quarantined or treated
for the illness. This may lead to interruptions in scheduled cases
depending on the length of absence. Consideration of clustered
scheduling using designated teams may be helpful in addressing inter-
ruptions due to the temporary absence of team personnel.
9 | CLINICAL TRIALS
Strong consideration should be given for deferral of all clinical trial
cases until after adequate resolution of the COVID-19 pandemic. This
recommendation should also be determined in accordance with institu-
tional research policies, as several institutions have limited enrollment
in clinical trials to only studies of lifesaving therapies during the pan-
demic. If patients being considered for clinical investigation become
clinically unstable during the COVID-19 pandemic, they should be
treated using commercially approved therapies. Continued follow-up of
patients already enrolled and treated should be maintained.
10 | CONCLUSIONS
The present COVID-19 pandemic has led heart teams to reprioritize
many SHD interventions considering the ongoing surge of other criti-
cally ill patients. The current pandemic will require physicians to make
challenging decisions regarding the proper triage and deferral of
patients as necessary. There remains significant uncertainty regarding
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the trajectory of the COVID-19 pandemic, but on the basis of the
experience of other nations, the U.S. health care system must be pre-
pared for a surge of critically ill patients in the coming weeks. A coor-
dinated multidisciplinary effort needs to occur to safely defer and
monitor patients with SHD requiring interventional therapies.
The coronavirus disease-2019 (COVID-19) pandemic has strained
health care resources around the world, causing many institutions to
curtail or stop elective procedures. This has resulted in an inability to
care for patients with valvular and structural heart disease in a timely
fashion, potentially placing these patients at increased risk for adverse
cardiovascular complications, including CHF and death. The effective
triage of these patients has become challenging in the current envi-
ronment as clinicians have had to weigh the risk of bringing suscepti-
ble patients into the hospital environment during the COVID-19
pandemic against the risk of delaying a needed procedure. In this doc-
ument, the authors suggest guidelines for how to triage patients in
need of structural heart disease interventions and provide a frame-
work for how to decide when it may be appropriate to proceed with
intervention despite the ongoing pandemic. In particular, the authors
address the triage of patients in need of transcatheter aortic valve
replacement and percutaneous mitral valve repair. The authors also
address procedural issues and considerations for the function of
structural heart disease teams during the COVID-19 pandemic.
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